Miyamoto H - Search Results

1

Influence of alcohol on newly developed metabolic dysfunction-associated fatty liver disease in both sexes: A longitudinal study.

Sogabe M, Okahisa T, Kagawa M, Ueda H, Kagemoto K, Tanaka H, Kida Y, Tomonari T, Taniguchi T, Okamoto K, Miyamoto H, Sato Y, Nakasono M, Takayama T. Sogabe M, et al. Among authors: miyamoto h. Clin Nutr. 2023 May;42(5):810-816. doi: 10.1016/j.clnu.2023.03.020. Epub 2023 Mar 31. Clin Nutr. 2023. PMID: 37043935 Free article.

2

Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation.

Yamasaki M, Sato Y, Okamoto K, Fukuya A, Kawaguchi T, Noda K, Kagemoto K, Mitsui Y, Miyamoto H, Takayama T. Yamasaki M, et al. Among authors: miyamoto h. Clin J Gastroenterol. 2023 Apr;16(2):180-186. doi: 10.1007/s12328-022-01736-z. Epub 2022 Nov 21. Clin J Gastroenterol. 2023. PMID: 36409453

3

Urokinase-type plasminogen activator blockade ameliorates experimental colitis in mice.

Kida Y, Okahisa T, Sato Y, Bando M, Fujimoto S, Ma B, Nakagawa T, Kawaguchi T, Nakamura F, Okamoto K, Miyamoto H, Sogabe M, Tsuneyama K, Takayama T. Kida Y, et al. Among authors: miyamoto h. Sci Rep. 2023 Feb 18;13(1):2899. doi: 10.1038/s41598-023-29824-1. Sci Rep. 2023. PMID: 36806262 Free PMC article.

4

A case of complete response with rechallenge-lenvatinib plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma refractory to multiple molecular-targeted agent treatments.

Tomonari T, Tanaka H, Tanaka T, Taniguchi T, Sogabe M, Kawano Y, Okamoto K, Miyamoto H, Sato Y, Takayama T. Tomonari T, et al. Among authors: miyamoto h. Clin J Gastroenterol. 2023 Jun;16(3):438-443. doi: 10.1007/s12328-023-01777-y. Epub 2023 Mar 1. Clin J Gastroenterol. 2023. PMID: 36856957

5

Clinical Outcomes of Comprehensive Genomic Profiling Tests for Gastrointestinal Cancers: Experience from Tokushima University Hospital.

Sato Y, Okada Y, Fujino Y, Kawaguchi T, Kida Y, Mitsui Y, Tanaka H, Tomonari T, Kitamura S, Okamoto K, Kawano Y, Miyamoto H, Sogabe M, Takayama T. Sato Y, et al. Among authors: miyamoto h. J Med Invest. 2023;70(1.2):154-159. doi: 10.2152/jmi.70.154. J Med Invest. 2023. PMID: 37164713 Free article.

6

Case Report: Longitudinal monitoring of clonal evolution by circulating tumor DNA for resistance to anti-EGFR antibody in a case of metastatic colorectal cancer.

Sagawa T, Sato Y, Hirakawa M, Hamaguchi K, Tamura F, Nagashima H, Fujikawa K, Okamoto K, Kawano Y, Sogabe M, Miyamoto H, Takayama T. Sagawa T, et al. Among authors: miyamoto h. Front Oncol. 2023 Jun 26;13:1203296. doi: 10.3389/fonc.2023.1203296. eCollection 2023. Front Oncol. 2023. PMID: 37434969 Free PMC article.

7

Efficacy of immune checkpoint inhibitors in patients with anorectal melanoma in association with immune-related adverse events: a case series.

Yokoyama R, Sato Y, Nakamura F, Kagemoto K, Mitsui Y, Okamoto K, Kawano Y, Sogabe M, Miyamoto H, Takayama T. Yokoyama R, et al. Among authors: miyamoto h. Clin J Gastroenterol. 2023 Dec;16(6):842-847. doi: 10.1007/s12328-023-01849-z. Epub 2023 Aug 26. Clin J Gastroenterol. 2023. PMID: 37632658

8

Lansoprazole inhibits the development of sessile serrated lesions by inducing G1 arrest via Skp2/p27 signaling pathway.

Kawaguchi T, Okamoto K, Fujimoto S, Bando M, Wada H, Miyamoto H, Sato Y, Muguruma N, Horimoto K, Takayama T. Kawaguchi T, et al. Among authors: miyamoto h. J Gastroenterol. 2024 Jan;59(1):11-23. doi: 10.1007/s00535-023-02052-0. Epub 2023 Nov 22. J Gastroenterol. 2024. PMID: 37989907

9

Association of metabolic dysfunction-associated fatty liver disease with gallstone development: A longitudinal study.

Sogabe M, Okahisa T, Kagawa M, Sei M, Kagemoto K, Tanaka H, Kida Y, Nakamura F, Tomonari T, Okamoto K, Miyamoto H, Sato Y, Nakasono M, Takayama T. Sogabe M, et al. Among authors: miyamoto h. J Gastroenterol Hepatol. 2024 Apr;39(4):754-761. doi: 10.1111/jgh.16483. Epub 2024 Jan 11. J Gastroenterol Hepatol. 2024. PMID: 38212880

10

A novel CT-based radiomics model for predicting response and prognosis of chemoradiotherapy in esophageal squamous cell carcinoma.

Kasai A, Miyoshi J, Sato Y, Okamoto K, Miyamoto H, Kawanaka T, Tonoiso C, Harada M, Goto M, Yoshida T, Haga A, Takayama T. Kasai A, et al. Among authors: miyamoto h. Sci Rep. 2024 Jan 23;14(1):2039. doi: 10.1038/s41598-024-52418-4. Sci Rep. 2024. PMID: 38263395 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,878 results

Search Page